Conference Coverage

Time reveals benefit of CABG over PCI for left main disease


 

REPORTING FROM TCT 2018

Study details

The MAIN-COMPARE analyses were based on 2,240 patients with unprotected left main coronary artery disease (stenosis of more than 50% and no coronary artery bypass grafts to the left anterior descending or the left circumflex artery) treated during 2000-2006.

A total of 1,102 patients underwent PCI with stenting: 318 in the era of bare-metal stents and 784 in the era of drug-eluting stents, predominantly sirolimus-eluting stents. A total of 1,138 patients underwent CABG. The minimum follow-up was 10 years in all patients, with a median of 12 years.

In the entire study cohort, PCI and CABG yielded similar rates of death (21.1% vs. 23.2%) and the composite of death, Q-wave myocardial infarction, or stroke (23.8% vs. 26.3%), but the PCI patients had a significantly higher rate of target vessel revascularization (21.1% vs. 5.8%), according to data reported at the meeting, which was sponsored by the New York–based Cardiovascular Research Foundation.

In analyses using a propensity score weighting technique, results for the entire cohort were much the same. But on stratification, PCI with drug-eluting stents versus CABG yielded higher risks of death (hazard ratio, 1.35; P = .05) and the composite adverse outcome (HR, 1.46; P = .009) from 5 years onward, as well as a sharply higher risk of target vessel revascularization for the full duration of follow-up (HR, 5.82; P less than .001).

Dr. Park disclosed that he had no conflicts of interest. The study was supported by the Korean Society of Interventional Cardiology and the CardioVascular Research Foundation of South Korea.

SOURCE: Park SJ et al. J Am Coll Cardiol. 2018 Sep 14. doi: 10.1016/j.jacc.2018.09.012).

Pages

Recommended Reading

New stroke intervention guidelines stress volume
MDedge Cardiology
Think DEB, not BMS, with high bleeding risk
MDedge Cardiology
FDA approves device for coronary artery perforations
MDedge Cardiology
ICYMI: Canakinumab reduced risk of gout attacks
MDedge Cardiology
Two red flags spell trouble ahead in spontaneous coronary artery dissection
MDedge Cardiology
Dapagliflozin meets endpoint in top-line DECLARE results, AstraZeneca says
MDedge Cardiology
Fish oil phoenix
MDedge Cardiology
Swings in four metabolic measures predicted death in healthy people
MDedge Cardiology
Simplified SYNTAX holds promise, but still has doubters
MDedge Cardiology
Get ready for high-sensitivity troponin tests in the ED
MDedge Cardiology